Randomised, double-blind, placebo-controlled study of safety, tolerability and efficacy of PBT2 in early to mid-stage Huntington disease
Huntington Disease
Enrolment: 109 · Results not recorded
Loading the evidence…
Drug
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Huntington Disease
Enrolment: 109 · Results not recorded
Alzheimer's Disease
Enrolment: 80 · Results not recorded
Healthy Volunteers
Enrolment: 18 · Results not recorded
Healthy Volunteers
Enrolment: 6 · Results not recorded
Healthy Volunteers
Enrolment: 18 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Controlled cortical impact traumatic brain injury
Acute post-injury PBT2 reduced lesion area, increased neuron number, decreased astrocytosis and normalised Y-maze performance, with effects emerging within days and maintained to 26 days post-injury.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.